Search Results - "Stadler, W M"

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC) by Molife, L. R., Attard, G., Fong, P. C., Karavasilis, V., Reid, A. H. M., Patterson, S., Riggs, C. E., Higano, C., Stadler, W. M., McCulloch, W., Dearnaley, D., Parker, C., de Bono, J. S.

“…Background: Histone deacetylase blockade can promote heat shock protein 90 (HSP90) acetylation, abrogating androgen receptor signaling. A phase II trial of the…”
Get full text

Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer by ARMSTRONG, A. J, HAGGMAN, M, CARDUCCI, M. A, PILI, R, STADLER, W. M, GINGRICH, J. R, ASSIKIS, V, POLIKOFF, J, DAMBER, J. E, BELKOFF, L, NORDLE, Ö, FORSBERG, G

“…Tasquinimod (Active Biotech) is an oral immunomodulatory, anti-angiogenic, and anti-metastatic agent that delayed metastatic disease progression in a…”
Get full text

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure by Dreicer, R., Stadler, W. M., Ahmann, F. R., Whiteside, T., Bizouarne, N., Acres, B., Limacher, J.-M., Squiban, P., Pantuck, A.

“…Summary Purpose : TG4010 is a recombinant MVA vector expressing the tumor-associated antigen MUC1 and IL2. We explored the effect two schedules of TG4010 on…”
Get full text

Novel approaches and future directions in castration-resistant prostate cancer by Nabhan, C., Parsons, B., Touloukian, E.Z., Stadler, W.M.

“…Recent advances in the treatment of castration-resistant prostate cancer (CRPC) have started to change the therapeutic landscape allowing clinicians to choose…”
Get full text

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer by Stadler, W M, Kuzel, T, Roth, B, Raghavan, D, Dorr, F A

“…To determine the activity of single-agent gemcitabine in previously untreated patients with metastatic transitional cell cancer. Forty patients with measurable…”
Get more information

Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling by Maitland, M L, Wu, K, Sharma, M R, Jin, Y, Kang, S P, Stadler, W M, Karrison, T G, Ratain, M J, Bies, R R

“…To improve future drug development efficiency in renal cell carcinoma (RCC), a disease‐progression model was developed with longitudinal tumor size data from a…”
Get full text

A phase I study of sirolimus and bevacizumab in patients with advanced malignancies by Cohen, E.E.W, Sharma, M.R, Janisch, L, Llobrera, M, House, L, Wu, K, Ramirez, J, Fleming, G.F, Stadler, W.M, Ratain, M.J

“…Abstract Background We performed a single institution, phase I study of sirolimus and bevacizumab, in order to determine the dose limiting toxicity (DLT) and…”
Get full text

Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor by Lacouture, M. E., Desai, A., Soltani, K., Petronic-Rosic, V., Laumann, A. E., Ratain, M. J., Stadler, W. M.

“…Summary The Ras–Raf–MEK–ERK signalling pathway is frequently dysregulated in human malignancies, as is angiogenesis and the vascular endothelial growth factor…”
Get full text

A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors by Desai, A. A., Schilsky, R. L., Young, A., Janisch, L., Stadler, W. M., Vogelzang, N. J., Cadden, S., Wright, J. A., Ratain, M. J.

“…Background:: This study of GTI-2040, a 20-mer phosphorothioate oligonucleotide complementary to the messenger ribonucleic acid (mRNA) of the R2 subunit of…”
Get full text

Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma by Aklilu, M., Stadler, W. M., Markiewicz, M., Vogelzang, N. J., Mahowald, M., Johnson, M., Gajewski, T. F.

“…Background: We postulated that in patients with metastatic renal cell carcinoma (RCC) or melanoma, depletion of normal B cells using the anti-CD20 mAb…”
Get full text

Kidney cancer by Vogelzang, Nicholas J, Stadler, Walter M

“…In the USA, the incidence of kidney cancer has increased 43% since 1973. The risk of the disorder is higher in men than in women and increases with age. The…”
Get full text

Flavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium Study by STADLER, W. M, VOGELZANG, N. J, AMATO, R, SOSMAN, J, TABER, D, LIEBOWITZ, D, VOKES, E. E

“…Flavopiridol is the first cyclin-dependent kinase (cdk) inhibitor to enter clinical trials. Serum levels of flavopiridol obtained during phase I studies were…”
Get full text

Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience by ARTZ, A. S, VAN BESIEN, K, ZIMMERMAN, T, GAJEWSKI, T. F, RINI, B. I, HU, H. S, STADLER, W. M, VOGELZANG, N. J

“…Nonmyeloablative allogeneic stem cell transplantation (NST) has considerable activity in patients with metastatic renal cell carcinoma (RCC), although there…”
Get full text

Mitogen-activated protein kinase kinase 4/stress-activated protein/erk kinase 1 (MKK4/SEK1), a prostate Cancer metastasis suppressor gene encoded by human chromosome 17 by YOSHIDA, B. A, DUBAUSKAS, Z, CHEKMAREVA, M. A, CHRISTIANO, T. R, STADLER, W. M, RINKER-SCHAEFFER, C. W

“…The introduction of a discontinuous approximately 70-cM portion of human chromosome 17 significantly suppresses the metastatic ability of AT6.1 rat prostate…”
Get full text

A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer by Rosenberg, A.J., Liao, C.-Y., Karrison, T., de Souza, J.A., Worden, F.P., Libao, B., Krzyzanowska, M.K., Hayes, D.N., Winquist, E., Saloura, V., Prescott, K., Villaflor, V.M., Seiwert, T.Y., Schechter, R.B., Stadler, W.M., Cohen, E.E.W., Vokes, E.E.

“…Multitargeted tyrosine kinase inhibitors (TKIs) of the vascular endothelial growth factor receptor (VEGFR) pathway have activity in differentiated thyroid…”
Get full text

Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer by RINI, B. I, VOGELZANG, N. J, DUMAS, M. C, WADE, J. L, TABER, D. A, STADLER, W. M

“…To determine the clinical response rate of the combination of weekly intravenous (IV) gemcitabine with continuous infusion fluorouracil (5-FU) in patients with…”
Get full text

Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma by STADLER, W. M, KUZEL, T, SHAPIRO, C, SOSMAN, J, CLARK, J, VOGELZANG, N. J

“…Renal cell carcinoma is resistant to most chemotherapy, and only a minority of patients respond to immunotherapy. Its highly vascular nature suggests that…”
Get full text

Development of target-based antineoplastic agents by STADLER, W. M, RATAIN, M. J

“…The elucidation of multiple potential targets in cancer cells and the development of multiple target-based antineoplastic agents provide unique challenges in…”
Get full text

Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model by Chugh, R, Griffith, K A, Davis, E J, Thomas, D G, Zavala, J D, Metko, G, Brockstein, B, Undevia, S D, Stadler, W M, Schuetze, S M

Get full text

Detection of Bladder Cancer Using a Novel Nuclear Matrix Protein, BLCA-4 by KONETY, B. R, NGUYEN, T.-S. T, DHIR, R, DAY, R. S, BECICH, M. J, STADLER, W. M, GETZENBERG, R. H

“…We have identified previously six nuclear matrix proteins (NMPs) that are bladder cancer specific. In this study, we analyzed the expression of one of these…”
Get full text